Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data
Six days after Genentech rolled out disappointing early-stage data on its IDO1 drug GDC-0919 (navoximod) in-licensed from NewLink Genetics, the big Roche subsidiary is kicking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.